Segment Information and Geographic Location Information (Tables)

12 Months Ended

Dec. 31, 2023

Segment Reporting [Abstract]

Components of Segment Revenues and Segment Adjusted EBITDA

Segment revenues and Segment Adjusted EBITDA for the years ended December 31, consisted of the following:

	2023						2022							2021
	Segment Revenues			Segment Adjusted  EBITDA			Segment Revenues			Segment Adjusted  EBITDA (3)				Segment Revenues			Segment Adjusted  EBITDA (3)
Assessment, Permitting and Response	$	220,727		$	52,148		$	187,234		$	37,458			$	261,865		$	57,128
Measurement and Analysis		197,095	(1)		37,217			172,432	(1)		31,588		(2)		153,208	(1)		31,270		(2)
Remediation and Reuse		206,386			27,087			184,750			30,616				131,340			19,326
Total Operating Segments		624,208			116,452			544,416			99,662				546,413			107,724
Corporate and Other		—			(37,876	)		—			(31,212	)			—			(30,082	)
Total	$	624,208		$	78,576		$	544,416		$	68,450			$	546,413		$	77,642

(1)Includes revenue of $8.8 million, $17.0 million and $23.9 million from the Discontinued Specialty Lab for the year ended December 31, 2023, 2022 and 2021, respectively.

(2)Includes Adjusted EBITDA of $2.1 million and $6.4 million from the Discontinued Specialty Lab for the year ended December 31, 2022 and 2021, respectively.

(3)Includes the add back of start-up losses and investment in new services of $2.3 million and $4.4 million for the year ended December 31, 2022 and 2021, respectively.

Reconciliation of Segment Measure to Net Loss

Presented below is a reconciliation of the Company’s segment measure to net loss for the years ended December 31:

	2023				2022				2021
Total	$	78,576			$	68,450			$	77,642
Interest expense, net		(7,793	)			(5,239	)			(11,615	)
Income tax benefit (expense)		980				(2,250	)			(1,709	)
Depreciation and amortization		(45,780	)			(47,479	)			(44,810	)
Stock-based compensation		(47,267	)			(43,290	)			(10,321	)
Start-up losses and investment in new services		—				(2,277	)			(4,407	)
Acquisition costs		(6,930	)			(1,891	)			(2,088	)
Fair value changes in financial instruments		4,129				3,396				(2,195	)
Fair value changes in business acquisition    contingencies		(84	)			3,227				(24,372	)
Discontinued Specialty Lab		(6,112	)	(1)		—				—
Expenses related to financing transactions		(35	)			(7	)			(50	)
Other losses or expenses, net		(543	)	(2)		(4,459	)	(3)		(1,400	)	(4)
Net loss	$	(30,859	)		$	(31,819	)		$	(25,325	)

(1)Amounts consist of operating losses before depreciation related to the Discontinued Specialty Lab, which include $2.2 million in current expected credit losses on the promissory note receivable issued upon the sale and a $1.8 million gain on the sale of its assets.

(2)Amounts are primarily comprised of lease abandonment charges and expenses related to an aircraft accident, partially offset by a gain on the surrender of a lease and an aircraft insurance gain.

(3)Amounts include costs associated with the exiting of the legacy water treatment and biogas operations and maintenance contracts and the Company's start-up lab in Berkley, California, as well as an impairment charge for certain operating lease right-of-use assets (Note 7) and severance costs related to the restructuring within the Company’s soil remediation business.

(4)Amounts include non-operational charges incurred due to the remeasurement of finance leases as a result of the adoption of ASC 842 and costs related to the implementation of a new ERP.

Schedule of Revenues by Geographic Location

The following table presents revenues by geographic location for the year ended December 31:

	2023		2022		2021
United States	$	539,578	$	523,189	$	526,672
Canada		72,608		12,002		10,358
Other international		12,022		9,225		9,383
Total Revenue	$	624,208	$	544,416	$	546,413